Trial reportPediatric pulmonology2011
Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection.
Trial report in Pediatric pulmonology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis.The Cochrane database of systematic reviews · 2021Pooled it
- Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.The Cochrane database of systematic reviews · 2020Pooled it
- Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.The Cochrane database of systematic reviews · 2020Pooled it
- Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.The Cochrane database of systematic reviews · 2017Pooled it
- Assembling the puzzle of antimicrobial resistance in staphylococcal biofilms.Emerging microbes & infections · 2026Article
- Systematic Review of Antimicrobial Therapies and Clinical Outcomes inLife (Basel, Switzerland) · 2026Review
- Sensor system for analysis of biofilm sensitivity to ampicillin.Applied microbiology and biotechnology · 2024Article
- Biofilm antimicrobial susceptibility testing: where are we and where could we be going?Clinical microbiology reviews · 2023Review
- Article
- Article
- Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023Article
- Establishing Antimicrobial Susceptibility Testing Methods and Clinical Breakpoints for Inhaled Antibiotic Therapy.Open forum infectious diseases · 2022Review
- Pseudomonas aeruginosa Volatilome Characteristics and Adaptations in Chronic Cystic Fibrosis Lung Infections.mSphere · 2020Article
- Improving antibiotic treatment of bacterial biofilm by hyperbaric oxygen therapy: Not just hot air.Biofilm · 2019Review
- Article
- Simple fluorometric-based assay of antibiotic effectiveness for Acinetobacter baumannii biofilms.Scientific reports · 2019Article
- Connecting iron acquisition and biofilm formation in the ESKAPE pathogens as a strategy for combatting antibiotic resistance.MedChemComm · 2019Review
- MBEC Versus MBIC: the Lack of Differentiation between Biofilm Reducing and Inhibitory Effects as a Current Problem in Biofilm Methodology.Biological procedures online · 2019Article
- Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections.Science translational medicine · 2018Article
- Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.The Cochrane database of systematic reviews · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 1 country.
Funding
Abstract
rationaleIn cystic fibrosis (CF), conventional antibiotic susceptibility results correlate poorly with clinical outcomes. We hypothesized that biofilm testing would more accurately reflect the susceptibilities of bacteria infecting CF airways.
methodsA multicenter randomized pilot trial was conducted to assess the efficacy and safety of using biofilm susceptibility testing of Pseudomonas aeruginosa sputum isolates to guide antibiotic regimens for chronic airway infections in clinically stable adolescent and adult CF patients. Thirty-nine participants were randomized to biofilm or conventional treatment groups; 14-day courses of two antibiotics were selected according to an activity-based algorithm using the corresponding susceptibility results.
resultsOf the agents tested, meropenem was most active against biofilm-grown bacteria, and was included in regimens for about half of each study group. For 19 of 39 randomized participants, randomization to the other study group would not have changed the antibiotic classes of the assigned regimen. Study groups were comparable at baseline, and had similar mean decreases in bacterial density, measured in log(10) colony forming units per gram of sputum (biofilm, -2.94 [SD 2.83] vs. conventional, -3.27 [SD 3.09]), and mean increases in forced expiratory volume in 1 sec, measured in liters (0.18 [SD 0.20] vs. 0.12 [SD 0.22]).
conclusionsIn this pilot study, antibiotic regimens based on biofilm testing did not differ significantly from regimens based on conventional testing in terms of microbiological and clinical responses. The predictive value of biofilm testing may nonetheless warrant evaluation in an adequately powered clinical trial in younger CF patients or those experiencing acute pulmonary exacerbation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.